UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
HOPEWELL PHARMA VENTURES, INC., Petitioner,
V.
MERCK SERONO SA, Patent Owner.
Case IPR2023-00480 Patent 7,713,947

## PATENT OWNER'S PRELIMINARY RESPONSE



## **TABLE OF CONTENTS**

1.	Introduction.					
II.	Background4					
III.	Person Of Ordinary Skill In The Art5					
IV.	V. Claim Construction					
V.	Petitioner Is Not Reasonably Likely To Prevail On Ground I10					
	A.	Petiti	oner Fails To Establish That Bodor And Stelmasiak			
		Discl	ose Or Suggest All Claim Limitations	16		
		1.	Neither Bodor Nor Stelmasiak Discloses Or Suggests			
			The Claimed Weight-Based Oral, Induction Or			
			Maintenance Dosing	16		
		2.	Neither Bodor Nor Stelmasiak Discloses Or Suggests A			
			Maintenance Period As Claimed	21		
	В.	Petiti	oner Has Not Established Any Motivation To Combine			
		Bodo	r With Stelmasiak To Arrive At The Challenged Claims	29		
		1.	A POSA Would Not Have Been Motivated To Adopt			
			Weight-Based Dosing	29		
		2.	A POSA Would Not Have Been Motivated To Combine			
			Bodor With Stelmasiak To Arrive At The Claimed			
			Induction Doses	30		



	3.	A POSA Would Not Have Been Motivated To Re-Treat		
		Patients After Bodor's 10-Month Cladribine-Free Period36		
	4.	A POSA Would Not Have Been Motivated To Combine		
		Bodor With Stelmasiak To Arrive At The Claimed 1.7		
		Mg/Kg Maintenance Dose		
	5.	Petitioner's Routine Optimization Arguments Fail To		
		Explain How A POSA Would Have Been Motivated To		
		Arrive At Claimed Dosing Methods		
C.	Petiti	oner Has Not Established Any Reasonable Expectation Of		
	Succ	ess In Combining Bodor's Method With Stelmasiak To		
	Arrive At The Challenged Claims			
	1.	A POSA Would Not Have Reasonably Expected To		
		Arrive At The Claimed Weight-Based Dosing45		
	2.	A POSA Would Not Have Reasonably Expected To		
		Arrive At The Claimed 1.7-3.5 Mg/Kg Total Induction		
		Period Dose By Modifying Bodor's Method In View Of		
		Stelmasiak		
	3.	A POSA Would Not Have Reasonably Expected To		
		Treat MS Using The Claimed About 8-10- Or 10-Month		



			Cladribine-Free Period By Modifying Bodor's Method In	
			View Of Stelmasiak	47
		4.	A POSA Would Not Have Reasonably Expected To	
			Arrive At The Claimed About 1.7 Mg/Kg Maintenance	
			Dose By Modifying Bodor's Method In View Of	
			Stelmasiak	48
		5.	A POSA Would Not Have Reasonably Expected To	
			Arrive At A Safe And Effective Method Of Treating MS	
			As Claimed By Modifying Bodor's Method In View Of	
			Stelmasiak	49
VI.	Obje	ctive I	ndicia Support Non-Obviousness	52
VII.	The Petition Should Be Denied Under 35 U.S.C. § 325(d)			52
	A.	The	Office Already Considered Petitioner's Alleged Prior Art	
		And	Arguments	52
		1.	Becton Dickinson Factors (a) And (b): Asserted Art Was	
			Considered During Examination	53
		2.	Becton Dickinson Factor (d): Petitioner's And The	
			Examiner's Arguments Are Not Materially Different	54
	B.	Petiti	ioner Has Not Identified A Material Error By The	
		Exan	niner	57



	1.	Becton Dickinson Factor (c): Asserted Art Was Evaluated	
		During Examination	58
	2.	Becton Dickinson Factor (e): Petitioner Has Not	
		Identified Material Examiner Error	60
	3.	Becton Dickinson Factor (f): Additional Evidence Does	
		Not Warrant Reconsideration	63
<b>3</b> 7111	C 1:		<i>C</i> 1



# DOCKET A L A R M

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

